Low TGF-β1 serum levels are a risk factor for atherosclerosis disease in ESRD patients

Kidney International

Volumn 61, Issue 1, 2002, Pages 324-335

  Stefoni, Sergio ^a   Cianciolo, Giuseppe ^a   Donati, Gabriele ^a   Dormi, Ada ^a   Grazia Silvestri, Maria ^a   Colì, Luigi ^a   De Pascalis, Antonio ^a   Iannelli, Sandra ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Atherosclerosis; Cardiovascular diseases; Hemodialysis; Ischemic heart disease; Uremia; Vascular complication

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ANALYTIC METHOD; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; EVALUATION; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; GENETICS; GENOTYPE; HEART MUSCLE ISCHEMIA; MIDDLE AGED; MORTALITY; PREDICTION AND FORECASTING; RENAL REPLACEMENT THERAPY; RISK FACTOR; STATISTICAL MODEL; SURVIVAL; UREMIA;

ADULT; AGED; AGED, 80 AND OVER; CORONARY ARTERIOSCLEROSIS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; RISK FACTORS; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UREMIA;

EID: 0036007133     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00119.x     Document Type: Article

References (65)

1. USRDS 1999 annual data report
2. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities
3. Cardiovascular disease in chronic renal failure: The challenge continues
4. Accelerated atherosclerosis in prolonged maintenance hemodialysis
5. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome)
6. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients
7. The Hemodialysis (HEMO) Study: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients
8. "U" curve association of blood pressure and mortality in hemodialysis patients
9. Atherosclerosis-an inflammatory disease
10. Effects of transforming growth factor β1 on growth of aortic smooth muscle cells
11. The serum concentration of active transforming growth factor β is severely depressed in advanced atherosclerosis
12. Cytokine expression in advanced human atherosclerotic plaques: Dominance of proinflammatory (Th1) and macrophage-stimulating cytokines
13. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries
14. Altered plasma levels of cytokines in patients with ischemic heart disease
15. Role of transforming growth factor β in human disease
16. Lipoprotein(a) induces cell growth in rat peritoneal macrophages through inhibition of transforming growth factor β activation
17. Regulation of murine type I plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta
18. TGF beta signals through a heterodimeric protein kinase receptor complex
19. Second generation logarithmic estimates of single pool variable-volume Kt/V: An analysis of error
20. TGF-beta1 DNA polymorphisms, protein levels, and blood pressure
21. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study
22. Genetic analysis of protein export in Escherichia coli K 12
23. TGFβ1 down-regulates inflammatory cytokine-induced VCAM-1 expression in cultured human glomerular endothelial cells
24. Peptide growth factors and their receptors from
25. Transforming growth factor beta 1 inhibits E-selectin expression on human endothelial cells
26. Transforming growth factor beta 1 and interleukin-l: A paradigm for opposing regulation of hematopoiesis
27. Inflammatory and immunomodulatory roles of TGF Beta 1
28. Modulation of cytokine production by transforming growth factor-beta
29. The expression of TGFβ receptors in human atherosclerosis: Evidence for acquired resistance to apoptosis due to receptor imbalance
30. Proliferation, migration, matrix turnover, and death of smooth muscle cells in native coronary and vein graft atherosclerosis
31. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth-factor beta 1
32. Endothelial cell adhesiveness for human T-lymphocytes is inhibited by transforming growth factor beta 1
33. Mechanisms of the protective effects of by transforming growth factor beta in reperfusion injury
34. Transforming growth factor β1 inhibits cytokine mediated induction of human metalloelastase in macrophages
35. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial
36. Transforming growth factor β hyperexpression in African American end stage renal disease patients
37. Active and acidactivable TGF-β in human sera, platelets and plasma
38. Expression of transforming growth factor β1 is increased in human vascular restenosis lesions
39. Antibodies against transforming growth factor β1 suppress intima hyperplasia in a rat model
40. Type beta transforming growth factor in human platelets: Release during platelet degranulation and action on vascular smooth muscle cells
41. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability
42. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop
43. Connective tissue growth factor. Friend or foe?
44. Apoptosis in restenosis versus stable angina atherosclerosis
45. Mediation of cardioprotection by transforming growth factor β
46. PDGF-AB release during and after haemodialysis procedure
47. Intra- and post-dialytic platelet activation and PDGF-AB release: Cellulose diacetate vs polysulfone membranes
48. Transforming growth factor β is sequestered into an inactive pool by lipoproteins
49. Hypoalbuminemia, cardiac morbidity, and mortality in end stage renal disease
50. The link of biocompatibility to cytokine production
51. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients
52. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
53. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells
54. Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apoprotein(a)
55. Lipoprotein(a) in renal disease
56. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients
57. Atherothrombogenicity of lipoprotein(a): The debate
58. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
59. Proliferation of human smooth muscle cells promoted by lipoprotein(a)
60. Plasminogen activator inibitor-1 activity in chronic renal disease and dialysis
61. Cardiovascular morbidity and endothelium dysfunction in chronic haemodialysis patients: Is homocyst(e)ine the missing link?
62. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients
63. Monocyte production of transforming growth factor β in long term hemodialysis: Modulation by hemodialysis membranes
64. Kinetics of technetium-labeled heparin in hemodialyzed patients
65. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge